)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Olympus
Olympus (7733) investor relations material
Olympus Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary7 Aug, 2026
Executive summary
Q1 FY2027 revenue rose 16.4% year-over-year to ¥240.4B, driven by strong growth in Gastrointestinal Solutions (GIS) and robust performance in North America, Europe, and APAC.
Adjusted operating margin improved to 12.8%, up 6.4pp YoY, supported by revenue growth, lower R&D and personnel expenses, and improved commercial execution.
Profit attributable to owners of parent more than doubled to ¥19.1B, with adjusted EPS up 130% YoY to ¥20 and comprehensive income at ¥28.0B.
The acquisition of BioProtect Ltd. was completed, expanding the portfolio in endoscopy-related therapeutic areas.
Full-year guidance reaffirmed, with structural tailwinds expected in H2 and key risks from FDA-related ship-holds being actively managed.
Financial highlights
Consolidated revenue: ¥240.4B (+16% YoY, +5% constant currency); gross profit: ¥156.8B; gross margin: 65.2%.
Adjusted operating profit: ¥30.7B (+133% YoY); operating profit: ¥28.95B (+74.4% YoY); adjusted operating margin: 12.8% (+6.4pp YoY).
Adjusted EPS: ¥20 (+130% YoY); basic EPS: ¥17.76; adjusted FCF: ¥9.2B (+¥26.7B YoY).
SG&A as % of revenue: 52.0% (-7.2pp YoY); SG&A expenses declined by 5.5% YoY on a constant currency basis.
Cash and cash equivalents decreased by ¥69.5B to ¥118.5B, mainly due to share repurchases and the BioProtect acquisition.
Outlook and guidance
Full-year revenue guidance: ¥1,055.0B to ¥1,076.0B (+4.4% to +6.5% YoY); operating profit expected at ¥155.5B (up 60.1%).
Adjusted operating margin expected at 15.2% to 16.7% (+1.0pp to +2.5pp YoY); adjusted EPS guidance: ¥106 to ¥119 (+15% to +29% YoY).
Profit attributable to owners of parent forecast at ¥109.0B (up 59.9%), with basic EPS of ¥102.26.
Year-end dividend guidance: ¥30 per share; no changes to previously announced guidance.
Shipment holds expected to be alleviated in H2, with most affected products returning to market.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Olympus
- FY2025 targets recovery after FY2024 earnings weakened under quality and impairment costs.7733
Q4 2024 - AI-driven innovation and a division-led model underpin 3–5% annual growth and margin gains.7733Status update
- Innovation, AI, and operational efficiency drive robust growth in endoscopy-enabled care.773344th Annual J.P. Morgan Healthcare Conference
- Global MedTech innovator advancing AI-driven endoscopy and sustainable healthcare solutions.7733Company presentation
- FY2027 guidance targets revenue growth, margin expansion, and continued capital returns.7733Q4 2026
- Q3 revenue rose 4% YoY, but profit guidance was cut on ship-holds, tariffs, and higher costs.7733Q3 2026
- Revenue and profit declined, but innovation and restructuring offer upside potential.7733Q2 2026
- Revenue and profit fell sharply, with guidance cut due to tariffs and regulatory headwinds.7733Q1 2026
- Q1 revenue up 15% and operating profit up 32%, with strong North America growth and stable outlook.7733Q1 2025
Next Olympus earnings date
Q2 202710 Nov, 2026
Olympus
Next Olympus earnings date
Q2 202710 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Olympus Corporation, established on October 12, 1919, is a global technology leader specializing in the design and delivery of innovative solutions for medical and surgical procedures, among other core areas. The company's primary focus lies in the manufacture and sales of precision machinery and instruments, particularly in the field of medical endoscopes, ultrasound, electrocautery, endotherapy, and cleaning and disinfection equipment. The company is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.